CA2586058A1 - Modified streptococcal polysaccharides and uses thereof - Google Patents

Modified streptococcal polysaccharides and uses thereof Download PDF

Info

Publication number
CA2586058A1
CA2586058A1 CA002586058A CA2586058A CA2586058A1 CA 2586058 A1 CA2586058 A1 CA 2586058A1 CA 002586058 A CA002586058 A CA 002586058A CA 2586058 A CA2586058 A CA 2586058A CA 2586058 A1 CA2586058 A1 CA 2586058A1
Authority
CA
Canada
Prior art keywords
polysaccharide
gbs
composition
polypeptide
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586058A
Other languages
English (en)
French (fr)
Inventor
Dennis L. Kasper
Hilde-Kari Guttormsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2586058A1 publication Critical patent/CA2586058A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002586058A 2004-11-01 2005-11-01 Modified streptococcal polysaccharides and uses thereof Abandoned CA2586058A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62390704P 2004-11-01 2004-11-01
US60/623,907 2004-11-01
PCT/US2005/039424 WO2006050341A2 (en) 2004-11-01 2005-11-01 Modified streptococcal polysaccharides and uses thereof

Publications (1)

Publication Number Publication Date
CA2586058A1 true CA2586058A1 (en) 2006-05-11

Family

ID=36319754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586058A Abandoned CA2586058A1 (en) 2004-11-01 2005-11-01 Modified streptococcal polysaccharides and uses thereof

Country Status (8)

Country Link
US (1) US7858101B2 (https=)
EP (1) EP1812057A4 (https=)
JP (1) JP2008518953A (https=)
CN (1) CN101107010A (https=)
AU (1) AU2005302269B2 (https=)
CA (1) CA2586058A1 (https=)
MX (1) MX2007005202A (https=)
WO (1) WO2006050341A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
GB201300707D0 (en) 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
EP3019515B1 (en) 2013-07-11 2019-08-21 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP3965826A1 (en) 2019-05-10 2022-03-16 GlaxoSmithKline Biologicals S.A. Conjugate production
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4207414A (en) 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4438261A (en) 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367221A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4367222A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367223A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4356263A (en) 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US5472696A (en) * 1988-02-26 1995-12-05 Univ. Of Florida Research Foundation, Inc. Antigen of group B streptococci
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
ES2160601T3 (es) 1992-09-24 2001-11-16 Brigham & Womens Hospital Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
PT1320542E (pt) 2000-08-08 2007-08-06 St Jude Childrens Res Hospital Ácidos nucleicos de estreptococo de grupo b, polipéptidos, composições terapêuticas e vacinas correspondentes
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
WO2006050341A3 (en) 2006-06-15
CN101107010A (zh) 2008-01-16
EP1812057A4 (en) 2009-07-22
US20060134142A1 (en) 2006-06-22
AU2005302269B2 (en) 2011-05-19
EP1812057A2 (en) 2007-08-01
JP2008518953A (ja) 2008-06-05
WO2006050341A2 (en) 2006-05-11
US7858101B2 (en) 2010-12-28
AU2005302269A1 (en) 2006-05-11
MX2007005202A (es) 2007-07-09

Similar Documents

Publication Publication Date Title
AU2023201579B2 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP2024112952A (ja) 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
RU2493870C2 (ru) Мультивалентная композиция на основе конъюгата пневмокковый полисахарид-белок
AU2005302269B2 (en) Modified streptococcal polysaccharides and uses thereof
KR20230058726A (ko) 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
BRPI0612656A2 (pt) composição imunogênica, vacina, e, kit de vacina para a administração concomitante ou seqüencial
KR20230021167A (ko) 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
Wu et al. Investigation of nontypeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines
Madoff et al. Surface structures of group B streptococci important in human immunity
HK40042634A (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131023